不同红细胞输血策略对神经重症患者预后影响的随机对照临床试验方案
本研究为单中心、前瞻性、随机对照试验方案,拟纳入234例神经重症患者,按1:1随机分为开放红细胞输血策略组(90 g/L)与限制性红细胞输血策略组(70 g/L),主要结局为出院时神经功能预后,并观察术后6个月格拉斯哥结局扩展量表评分、院内死亡率、输血反应及全身并发症发生率。
要点
- 拟纳入234例神经重症患者,1:1随机分为开放输血策略组(90 g/L)与限制性输血策略组(70 g/L)。
- 主要结局为出院时神经功能预后,次要结局包括术后6个月格拉斯哥结局扩展量表评分、院内死亡率等。
- 研究在围手术期血液保护基础上进行,术中采用自体输血,为既往研究未涉及的内容。
核心结论
- 神经重症患者输血策略存在争议,需探索更适合这类患者的输血策略;本研究结果将为神经重症患者血制品使用提供理论依据。
研究设计与样本
- 单中心、前瞻性、随机对照临床试验方案,拟纳入234例神经重症患者,按1:1随机分为开放红细胞输血策略组(90 g/L)与限制性红细胞输血策略组(70 g/L)。
- 研究在围手术期血液保护基础上进行,术中采用自体输血。
- 试验已在中国临床试验注册中心注册(ChiCTR2400083713),注册日期为2024年4月30日,并经首都医科大学附属北京天坛医院伦理委员会批准(KY2023-116-03)。
主要发现
- 原文为试验方案,尚未报告结局数据。
- 主要结局为出院时神经功能预后;安全性与有效性指标包括术后6个月格拉斯哥结局扩展量表评分、院内死亡率、输血反应发生率及全身并发症发生率。
关键数值与推荐
- 开放红细胞输血策略组阈值:90 g/L;限制性红细胞输血策略组阈值:70 g/L。
- 主要结局:出院时神经功能预后。
- 次要指标:术后6个月格拉斯哥结局扩展量表评分、院内死亡率、输血反应发生率、全身并发症发生率。
临床怎么用
- 原文为试验方案,未据结果给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Neurocritical diseases such as subarachnoid hemorrhage, traumatic brain injury, and cerebral hemorrhage are the main cause of death and long-term disability. Red blood cell (RBC) transfusion can improve the oxygen supply to the brain, but may lead to complications such as cerebral vasospasm. The optimal threshold is unknown. We conducted a randomized trial to explore the optimal RBC transfusion strategy for neurocritical patients based on perioperative blood protection: liberal RBC transfusion strategy or restrictive RBC transfusion strategy. METHODS: This is a single-center, prospective, randomized, controlled trial. A total of 234 neurocritical patients will be randomly assigned to the liberal RBC transfusion strategy (90 g/L) group and the restrictive RBC transfusion strategy (70 g/L) group in a 1:1 ratio. The primary outcome is the neurological outcome at discharge. Further safety and efficacy parameters include the Glasgow Outcome Scale extended score at 6 months after surgery, in-hospital mortality, the incidence of transfusion reactions, and the incidence of systemic complications. DISCUSSION: This is a prospective randomized controlled study to investigate the effect of a liberal RBC transfusion strategy (90 g/L) versus a restrictive RBC transfusion strategy (70 g/L) on the outcome of neurocritical patients. Transfusion strategies for neurocritical patients with impaired autoregulation of cerebral blood flow have been controversial, so it is necessary to explore transfusion strategies that are more suitable for these patients. This study will be carried out on the basis of blood protection, that is, intraoperative autotransfusion will be used during the surgery, which was not involved in previous studies. The results of this study will provide a theoretical basis for the use of blood products in neurocritical patients. TRIAL REGISTRATION: This study conforms to the principles of the Helsinki Declaration. This trial is registered at the Chinese Clinical Trial Registry (ChiCTR2400083713) on April 30, 2024. Before the study started, it was approved by the Ethics Committee of Beijing Tiantan Hospital, Capital Medical University (KY2023-116-03).
引用
- Fu Y, Lu R, Wang T, et al. Effect of different red blood cell transfusion strategies on the outcome of neurocritical patients: a randomized, controlled, clinical trial protocol. Trials. 2025. PMID: 41299708. doi:10.1186/s13063-025-09277-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。